101 related articles for article (PubMed ID: 30915204)
1. Patterns of prescribing hydroxyurea for sickle cell disease patients from a central hospital, Saudi Arabia.
Elghazaly AA; Aljatham AA; Khan AM; Elneil RM; Jafar SZS; Elwishy SA; Ahmed OE; Bughnah AM; Ibrahim MH
Hematol Rep; 2019 Feb; 11(1):7860. PubMed ID: 30915204
[TBL] [Abstract][Full Text] [Related]
2. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia.
Alsalman M; Alkhalifa H; Alkhalifa A; Alsubie M; AlMurayhil N; Althafar A; Albarqi M; Alnaim A; Khan AS
Health Sci Rep; 2021 Dec; 4(4):e437. PubMed ID: 34786489
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoepidemiological study of prescription pattern in outpatient clinics in Southwestern Saudi Arabia.
Irshaid YM; Al-Homrany MA; Hamdi AA; Adjepon-Yamoah KK; Mahfouz AA
Saudi Med J; 2004 Dec; 25(12):1864-70. PubMed ID: 15711656
[TBL] [Abstract][Full Text] [Related]
7. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
8. Prescribing of potentially inappropriate medications among the elderly population in an ambulatory care setting in a Saudi military hospital: trend and cost.
Al-Omar HA; Al-Sultan MS; Abu-Auda HS
Geriatr Gerontol Int; 2013 Jul; 13(3):616-21. PubMed ID: 23035714
[TBL] [Abstract][Full Text] [Related]
9. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
10. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
[TBL] [Abstract][Full Text] [Related]
11. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
[TBL] [Abstract][Full Text] [Related]
12. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
Lanzkron S; Haywood C; Hassell KL; Rand C
J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
[TBL] [Abstract][Full Text] [Related]
13. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
15. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia.
Gohal GA; Gosadi IM; Cittana Iqbal BA; Ghazwani YH; Daghriri AM; Shugairi AA; Daghriri KA; Zurayyir AJ; Nemri AA; Abdulhaq MA
Patient Prefer Adherence; 2022; 16():3059-3067. PubMed ID: 36387052
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
[TBL] [Abstract][Full Text] [Related]
19. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
Sneed RC; May WL; Stencel C
Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman.
Jose J; Elsadek RA; Jimmy B; George P
Oman Med J; 2019 Jul; 34(4):327-335. PubMed ID: 31360322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
